• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Antidepressant Updates

Antidepressant Updates

January 1, 2004
Daniel Carlat, MD
From The Carlat Psychiatry Report
Issue Links: Editorial Information | PDF of Issue
Daniel Carlat, MD Dr. Carlat has disclosed that he has no significant relationships with or financial interests in any commercial companies pertaining to this educational activity.

Sorry, no earthshaking developments in the antidepressant world in 2003, but here are some developments that you’ll find useful in your practice.

Coming soon. Symbiax. Or so say the ads, indicating that it is on the verge of FDA approval. Brought to you by Eli Lilly, it is a combination of Prozac and Zyprexa. The word on the street is that it will be approved for bipolar depression. It’s an updated version of “Triavyl”, a combination of Trilafon and Elavil that is being marketed and consumed by many grateful patients to this very day.

Serzone is getting an increasingly harsh reception around the world. Since its approval in the United States in 1994, it has been linked to 55 cases of liver failure, including 20 deaths. In January 2003, Bristol Myers Squibb voluntarily withdrew the drug from the entire European market, and in November Canadian regulators kicked it out of town. Serzone is now only available in the U.S. and Australia, but probably not for long: Public Citizen, the consumer group founded by Ralph Nader, has sent a petition to the FDA calling for removal of Serzone from the U.S. market ASAP.

Provigil is gaining popularity among psychiatrists, both as a treatment for residual symptoms of depression and for ADHD. The first placebocontrolled study for treatment of depression was just published (DeBattista et al, J Clin Psychiatry 2003;64:1057-1064). Enrolled patients were partial responders to antidepressants, and were randomly assigned to 6 weeks of either Provigil 100-400 mg QD, or placebo. The Provigil patients were less sleepy and fatigued than placebo patients by week two, but placebo caught up to Provigil by week 6. There were no differences between the groups in overall depression scores. Bottom line is that, yes, Provigil wakes sleepy patients up quickly, but after a few weeks it may have little additive effect. Caveat: The FDA has not approved Provigil for use in anything other than narcolepsy. However, in November an advisory panel recommended that it should be approved for sleepiness associated with both sleep apnea and shift work.

Paxil CR treats the hot flashes of menopause pretty well. A recent study (Stearns et al., JAMA. 2003;289:2827- 2834) showed that hot flash composite scores were reduced by 62% in those receiving 12.5 mg/d of Paxil CR, 64% in those receiving 25 mg QD, and 39% in the placebo group. There is now something of a hot flash war among newer antidepressants: Prozac leads to a 50% reduction over 4 weeks at 20 mg/d, and Effexor XR causes a 61% reduction over 4 weeks at 75 mg QD and 150 mg QD. Estrogen, the gold standard, typically reduces them by 80%.

Wellbutrin XL was approved for depression in August of 2003. It can be dosed once a day; it comes in 150 mg and 300 mg tablets, and the maximum recommended dose is 450 mg QD. You can switch directly from either IR or SR Wellbutrin to the same dosage of XL. All the usual seizure cautions apply-don't give it to patients with a history of seizures or eating disorders, and don’t go higher than 450 mg unless you like living dangerously. You'll notice that GlaxoSmithKline, the manufacturer, is saturating the airwaves with direct to consumer ads for XL. The reason for this push, of course, is that Eon Pharmaceuticals announced in November that it had received FDA approval for a generic version of Wellbutrin SR. GSK is suing Eon as a delaying tactic, but that won't prevent generic SR from reaching a pharmacy near you.

Remeron for Sleep Apnea. Now you can offer your sleep apnea patients something besides sympathy and support. Dr. David Carley, a sleep researcher at the University of Illinois Chicago, reported the results of a study of Remeron given to 12 patients with sleep apnea. A crossover study, the patients were divided into three groups of 4, and each group tried each of the following treatments on alternate weeks: placebo, Remeron 4.5 mg QD, and Remeron 15 Q D. The 15 mg dose beat placebo in reducing episodes of apnea and in reducing sleep disruptions. This was presented at the 2003 meeting of the Associated Professional Sleep Societies. And yes, it was funded by Organon.

Substance P blocker doesn't work. Merck & Co. announced on Nov 12 that aprepitant, its Substance P Antagonist (SPA), had failed antidepressant trials and would no longer be developed as a potential antidepressant. Merck isn't the only one who is disappointed. Psychiatrists throughout the world were hoping for some relief from the barrage of copycat SSRIs and SNRIs that have been flooding the market.

Generic Watch: Fluoxetine (generic of Prozac) is getting cheaper and cheaper, but tell your patients it pays to shop around. Some pharmacies make big bucks on marking up generics. North of Boston, the price for one month of fluoxetine (20 mg QD) varies from $25 to $50....Paroxetine has gone generic, in case you hadn’t heard. But it’s not much of a bargain at $75-$90 per month (20 mg QD), only $20 cheaper than Paxil....And don’t forget about bupropion IR (the generic version of Wellbutrin IR), 60% cheaper than Wellbutrin XL and every nanometer the same molecule.

TCR VERDICT: O Blockbuster, Where are You Now?
General Psychiatry
KEYWORDS antidepressants
    Carlat 150x150
    Daniel Carlat, MD

    Medication Fact Book for Psychiatric Practice, Seventh Edition (2024)

    More from this author
    www.thecarlatreport.com
    Issue Date: January 1, 2004
    SUBSCRIBE NOW
    Table Of Contents
    The First ECT
    Dr. John O’Reardon on Antidepressant Augmentation
    Antidepressant Updates
    ECT: The Very Latest
    Cymbalta: Dual the Reuptake, Triple the Hype
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.